MyoKardia, Inc. (MYOK): Price and Financial Metrics
GET POWR RATINGS... FREE!
MYOK Stock Summary
- MYOK's price/sales ratio is 283.62; that's higher than the P/S ratio of 98.98% of US stocks.
- Over the past twelve months, MYOK has reported earnings growth of 292.69%, putting it ahead of 95.71% of US stocks in our set.
- As for revenue growth, note that MYOK's revenue has grown -53.7% over the past 12 months; that beats the revenue growth of merely 3.04% of US companies in our set.
- Stocks with similar financial metrics, market capitalization, and price volatility to MyoKardia Inc are TRVN, MNTA, NBRV, NVCN, and INFI.
- Visit MYOK's SEC page to see the company's official filings. To visit the company's web site, go to www.myokardia.com.
MYOK Stock Price Chart Interactive Chart >
MYOK Price/Volume Stats
|Current price||$224.91||52-week high||$225.00|
|Prev. close||$224.80||52-week low||$42.65|
|Day high||$225.00||Avg. volume||752,969|
|50-day MA||$186.80||Dividend yield||N/A|
|200-day MA||$108.27||Market Cap||11.99B|
MyoKardia, Inc. (MYOK) Company Bio
MyoKardia is a clinical stage biopharmaceutical company pioneering a precision medicine approach to discover, develop and commercialize targeted therapies for the treatment of serious and neglected rare cardiovascular diseases
MYOK Latest News Stream
|Loading, please wait...|
MYOK Latest Social Stream
View Full MYOK Social Stream
Latest MYOK News From Around the Web
Below are the latest news stories about MyoKardia Inc that investors may wish to consider to help them evaluate MYOK as an investment opportunity.
The Daily Biotech Pulse: Moderna Inks 2 R&D Deals, BioNTech To Buy Manufacturing Facility, Dyne Therapeutics IPO
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 16) Arena Pharmaceuticals, Inc. (NASDAQ: ARNA ) (the first subject has been dosed in a Phase 3 trial evaluating etrasimod for the potential treatment of moderately to severely active ulcerative colitis) Beigene Ltd (NASDAQ: BGNE ) BioLife Solutions Inc (NASDAQ: BLFS ) Checkpoint Therapeutics Inc (NASDAQ: CKPT ) Denali Therapeutics Inc (NASDAQ: DNLI ) Dr.Reddy's Laboratories Ltd (NYSE: RDY ) (announced a deal with Russia for 100 million doses of Sputnik-V vaccine against the coronavirus) Fortress Biotech (NASDAQ: FBIO ) Guardant Health Inc (NASDAQ: GH ) Immunovant Inc (NASDAQ: IMVT ) Insmed Incorporated (NASDAQ: INSM ) InVitae Corp (NYSE: NVTA ) ...
The Daily Biotech Pulse: Moderna Expands Into Switzerland, Tiziana To Spin Off Testing Unit, Metacrine IPO
Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 15) Avidity Biosciences Inc (NASDAQ: RNA ) Beigene Ltd (NASDAQ: BGNE ) Bicycle Therapeutics PLC (NASDAQ: BCYC ) BioLife Solutions Inc (NASDAQ: BLFS ) Checkpoint Therapeutics Inc (NASDAQ: CKPT ) Denali Therapeutics Inc (NASDAQ: DNLI ) Fate Therapeutics Inc (NASDAQ: FATE ) Guardant Health Inc (NASDAQ: GH ) Horizon Therapeutics PLC (NASDAQ: HZNP ) Immunovant Inc (NASDAQ: IMVT ) InVitae Corp (NYSE: NVTA ) Jounce Therapeutics Inc (NASDAQ: JNCE ) Marinus Pharmaceuticals Inc (NASDAQ: MRNS ) ( announced a positive late-stage readout for ganaxolone) Mirati Therapeutics Inc (NASDAQ: MRTX ) Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA ) Myokardia Inc (NASDAQ: MYOK ) Novocure Ltd (NASDAQ: NVCR ) Outset Medical Inc (NASDAQ: OM ) (more than...
The following slide deck was published by MyoKardia, Inc. in conjunction with this event....
BRISBANE, Calif., July 28, 2020 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK), today announced that it will report second quarter financial and…
Hypertrophic Cardiomyopathy Pipeline 2020 Featuring Algomedix, Celltrion, MyoKardia, Novartis and 4 Others - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--The "Hypertrophic Cardiomyopathy Pipeline Research Monitor, 2020 - Drugs, Companies, Clinical Trials, R&D Pipeline Updates, Status and Outlook" report has been added to ResearchAndMarkets.com's offering. PIPELINE HIGHLIGHTS Hypertrophic Cardiomyopathy is one of the widely researched conditions during 2020 with 8 companies actively focusing on realizing pipeline's potential. Development of Hypertrophic Cardiomyopathy medicines is identified as integral to the strateg
MYOK Price Returns